XML 112 R71.htm IDEA: XBRL DOCUMENT
v3.20.2

Fair Value of Financial Instruments (Tables) (Brooklyn ImmunoTherapeutics, LLC) | 9 Months Ended
--- | ---
Sep. 30, 2020
Brooklyn Immunotherapeutics, LLC [Member] |
Schedule of Fair Value of Liabilities | The following tables summarize the liabilities that are measured at fair value as of September 30, 2020 and December 31, 2019:
|  | September 30, 2020 |
Description |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Liabilities: |  |  |  |  |  |  |  |  |
Contigent consideration |  |  | - |  |  |  | - |  |  |  | 870,000 |
Total |  | $ | - |  |  | $ | - |  |  | $ | 870,000 |
|  | December 31, 2019 |
Description |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Liabilities: |  |  |  |  |  |  |  |  |
Contigent consideration |  |  | - |  |  |  | - |  |  |  | 870,000 |
Total |  | $ | - |  |  | $ | - |  |  | $ | 870,000 |

X
- Definition Tabular disclosure of derivative liabilities at fair value. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |